Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ECTRIMS 2022 | Screening tools to detect cognitive impairment in MS patients

Cognitive impairment occurs in up to 40-65% of multiple sclerosis (MS) patients. Celia Oreja-Guevara, MD, PhD, University Hospital San Carlos, Madrid, Spain, discusses a study evaluating the best screening tool for cognitive impairment. The study assessed the value of Symbol Digit Modalities Test (SDMT) and Montreal Cognitive Assessment (MoCA) test as cognitive tools in MS patients. Interestingly, the results showed statistically significant differences in SDMT between healthy controls and MS patients but no statistically significant differences in MoCA between the two groups. These results indicate that SDMT seems to be a valuable and sensitive tool for screening for cognitive impairment in MS patients. This interview took place at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress 2022 in Amsterdam, The Netherlands.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


C Oreja-Guevara has received honoraria for speaking and serving on advisory boards from Biogen Idec., F. Hoffmann-La Roche Ltd, Sanofi-Genzyme, Merck, Janssen, BMS, Novartis, and Teva.